Adverse drug reaction patterns of GLP ‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database
Diabetes, Obesity and Metabolism · 2025-06 · 27 (6) · 3490-3502
DOI: 10.1111/dom.16376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 02.04.2025. Verfasst von Tae Hyeon Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, …. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptides, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Aims
This study aims to compare adverse drug reaction patterns of liraglutide, semaglutide and tirzepatide—glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) approved for anti‐obesity medications—to evaluate their real‐world safety. Materials and Methods This disproportionality analysis utilized a case–control design with VigiBase. The study focused on reports of adverse events associated with liraglutide, semaglutide and tirzepatide, selected based on warnings in the US Food and Drug Administration approval labels for each drug. Data were restructured using unique identifiers to differentiate individuals affected by adverse drug reactions. Multivariable logistic regression models estimated adjusted reporting odds ratios (aRORs) with 95% confidence intervals (CIs) to assess the association between various adverse events and GLP‐1 RAs, adjusting for age, sex, region, reporter qualification, reporting year and concomitant medication. The information component (IC) was analysed, and signals of adverse drug reactions were considered significant only when both aROR and IC were statistically significant.
Results
Our analysis of targeted adverse drug reactions included 24 725 individuals using liraglutide, 21 454 using semaglutide and 11 538 using tirzepatide. Tirzepatide had fewer reports of adverse drug reactions compared with the other two drugs, and its pharmacovigilance association strength was the lowest. Semaglutide, however, was significantly associated with several unusual adverse events, including suicidal ideation and behaviour (IC, 1.53 [IC 025 , 1.28]; aROR, 2.52 [95% CI, 2.18–2.93]), hair loss (IC, 0.78 [IC 025 , 0.63]; aROR, 1.42 [95% CI, 1.30–1.55]) and vision loss (IC, 1.27 [IC 025 , 1.13]; aROR, 1.80 [95% CI, 1.66–1.97]).
Conclusions
Our findings emphasize the need for cautious prescribing and further research to ensure the safe use of these medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
- Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
- Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.
- Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
- Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea.
- Department of Electronics and Information Convergence Engineering, Kyung Hee University, Yongin, South Korea.
ORCID-Profile: Dong Keon Yon
Förderung
- Ministry of Science and ICT, South Korea
Zitieren
APA
Kim, T. H., Lee, K., Park, S., Oh, J., Park, J., Jo, H., Lee, H., Cho, J., Wen, X., Cho, H., Kim, S., & Yon, D. K. (2025). Adverse drug reaction patterns of GLP ‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database. Diabetes, Obesity and Metabolism, 27(6), 3490-3502. https://doi.org/10.1111/dom.16376
Vancouver
Kim TH, Lee K, Park S, Oh J, Park J, Jo H, et al. Adverse drug reaction patterns of GLP ‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database. Diabetes, Obesity and Metabolism. 2025;27(6):3490-3502. doi:10.1111/dom.16376
BibTeX
@article{Kim2025,
author = {Kim, Tae Hyeon and Lee, Kyeongmin and Park, Seoyoung and Oh, Jiyeon and Park, Jaeyu and Jo, Hyesu and Lee, Hayeon and Cho, Jaehyeong and Wen, Xuerong and Cho, Hanseul and Kim, Sunyoung and Yon, Dong Keon},
title = {Adverse drug reaction patterns of GLP ‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {6},
pages = {3490--3502},
doi = {10.1111/dom.16376}
}
EUVIMED